Global Hemophilia Market Report 2022: Rising Adoption of Prophylaxis Treatment to Drive Sector Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hemophilia Market Analysis by Type (Type A, B, C,), by Treatment (Prophylaxis, On-Demand), by Therapy (Gene, Replacement, Immune Tolerance Induction (ITI) Therapy), and by Region - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The global hemophilia market size is estimated to be USD 12.6 billion in 2021 and is expected to witness a CAGR of 5.79% during the forecast period. Rising adoption of prophylaxis treatment is a key driver for the growth of the global hemophilia market.

Additionally, increasing cases of hemophilia in new-borns, growing investment in R&D activities for new product development, and rise in favourable initiatives taken by the government are some of the other drivers propelling the market growth. Nevertheless, lack of knowledge regarding hemophilia among developing economies and low acceptance rates of advanced products are expected to restrain the global market growth.

Regional Insights

In 2021, North America accounted for the largest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the growing consciousness about the benefits of early detection of hemophilia, favourable reimbursement policies by the government, and increasing preference for prophylaxis treatment in this region.

Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the growing number of hemophilic patients, introduction of new drugs in the market, and increasing awareness regarding technologically advanced products in this region.

Market Segmentation

Hemophilia Market, By Type (Revenue, USD Billion, 2021 - 2029)

• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

Hemophilia Market, By Treatment (Revenue, USD Billion, 2021 - 2029)

• Prophylaxis
• On-demand

Hemophilia Market, By Therapy (Revenue, USD Billion, 2021 - 2029)

• Gene therapy
• Replacement therapy
• ITI therapy

Hemophilia Market, By Region (Revenue, USD Billion, 2021 - 2029)

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• SpainoItaly
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• Saudi Arabia
• Rest of MEA

Key Topics Covered:

1. Research Methodology

2. Introduction: Hemophilia

3. Executive Summary

4. Market Dynamics

5. Market Environment Analysis

6. COVID-19 Impact Analysis: Hemophilia Market

7. Market Analysis by Type

8. Market Analysis by Treatment

9. Market Analysis by Therapy

10. Regional Market Analysis

11. North America Hemophilia Market

12. Europe Hemophilia Market

13. Asia Pacific Hemophilia Market

14. Latin America Hemophilia Market

15. MEA Hemophilia Market

16. Competitor Analysis

17. Company Profiles

18. Conclusion & Recommendations

Companies Mentioned

• Novo Nordisk A/S (Denmark)
• Shire plc (U.S.)
• Chugai Pharmaceutical Co. Ltd. (Japan)
• Bayer AG (Germany)
• Pfizer Inc. (U.S.)
• CSL Behring (U.S.)
• BioMarin (U.S.)
• Octopharma AG (Switzerland)
• Genzyme Corporation (U.S.)
• Spark Therapeutics Inc. (U.S.)

For more information about this report visit https://www.researchandmarkets.com/r/epche1

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900